Norgine Drives Role As Specialty Partner For Europe
Separates Out Consumer Healthcare Business
The mid-sized pharmaceutical company Norgine aims to grow its specialty business in Europe through targeted business development activities, while at the same time separating out its consumer healthcare activities into a new subsidiary.
You may also be interested in...
Asia Deal Watch: Zhaoke, PanOptica Finalize Neovascular Eye Disease Alliance
Plus deals involving Zai Lab/MacroGenics, Ono/Rafael Pharmaceuticals, Beijing Podconley/Norgine, Nuance/Verona and BeiGene/Shoreline.
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Netherlands’ Norgine Sets Up OTC Business And Targets Acquisitions
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.